Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by Pandoraon Nov 29, 2022 5:20pm
139 Views
Post# 35137965

RE:RE:RE:Biorun and Navajojoe

RE:RE:RE:Biorun and Navajojoe
navajojoe wrote:
SironaInvestor wrote: Unfortunately nothing to add. And in addition of that, they ratify the nice incentive plan on the 30th November when Howard and Chris sitting under the Christmas tree with a nice reindeer jumper and celebrate the success of the company!! 


Unfortunately that is the way of the Venture Exchange. The vast majority of the penny stocks that trade on that bourse are there to make those in management rich, regardless whether or not their shareholders ever see a profit. Anyone who buys one of those stocks should realise that long before they ever make a trade. And like most, this company is very good at blowing sunshine up our collective butts. It is truly sad that they never seem to actually accomplish anything substantial.

But, I have seen similar stories that have gone on for years, that suddenly break out on one really good deal. We have some interesting science to sell, and maybe, just maybe, Abbvie might turn out to be our white knight. As sad and pathetic as that is, I still have hope.


That does appear to be a very common problem on the Venture companies. The CEO's seem to receive such high annual salaries that there is not a lot of incentive to increase the share price. The shareholders in the meantime are looking for a value add because they don't have the security of the annual salary input to their bank account.

One of the most common moves with the Venture companies is "financings" and the major output of these financings is to keep the ledger positive enough to maintain management salaries - year after year after year. Why would they need to increase shareholder value although they always make that as a claim of their objectives. Number one or number two "provide shareholder value". But when they fail in that regard nothing changes in their personal added value plan.
<< Previous
Bullboard Posts
Next >>